Literature DB >> 31048356

Ibrutinib reduces obinutuzumab infusion-related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels.

Juliana Velez Lujan1, Paula A Lengerke-Diaz2, Chaja Jacobs1, Eider F Moreno-Cortes2, Cesar A Ramirez-Segura2, Michael Y Choi1, Colin McCarthy1, Alaina Heinen1, Thomas J Kipps1, Januario E Castro3,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31048356      PMCID： PMC6939526          DOI： 10.3324/haematol.2018.212597

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions.

Authors:  Ciara L Freeman; Franck Morschhauser; Laurie Sehn; Mark Dixon; Richard Houghton; Thierry Lamy; Günter Fingerle-Rowson; Elisabeth Wassner-Fritsch; John G Gribben; Michael Hallek; Gilles Salles; Guillaume Cartron
Journal:  Blood       Date:  2015-10-07       Impact factor: 22.113

2.  Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.

Authors:  Valentin Goede; Kirsten Fischer; Raymonde Busch; Anja Engelke; Barbara Eichhorst; Clemens M Wendtner; Tatiana Chagorova; Javier de la Serna; Marie-Sarah Dilhuydy; Thomas Illmer; Stephen Opat; Carolyn J Owen; Olga Samoylova; Karl-Anton Kreuzer; Stephan Stilgenbauer; Hartmut Döhner; Anton W Langerak; Matthias Ritgen; Michael Kneba; Elina Asikanius; Kathryn Humphrey; Michael Wenger; Michael Hallek
Journal:  N Engl J Med       Date:  2014-01-08       Impact factor: 91.245

3.  Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia.

Authors:  John C Byrd; Joseph M Flynn; Thomas J Kipps; Michael Boxer; Kathryn S Kolibaba; David J Carlile; Guenter Fingerle-Rowson; Nicola Tyson; Jamie Hirata; Jeff P Sharman
Journal:  Blood       Date:  2015-10-15       Impact factor: 22.113

4.  Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms.

Authors:  M Ruella; S S Kenderian; O Shestova; M Klichinsky; J J Melenhorst; M A Wasik; S F Lacey; C H June; S Gill
Journal:  Leukemia       Date:  2016-09-28       Impact factor: 11.528

5.  Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial.

Authors:  Jennifer R Brown; Susan O'Brien; C Daniel Kingsley; Herbert Eradat; John M Pagel; James Lymp; Jamie Hirata; Thomas J Kipps
Journal:  Blood       Date:  2015-03-13       Impact factor: 22.113

6.  Severe infusion-related reactions are uncommon in rituximab-treated CLL patients in clinical practice: results from a Swedish national observational study.

Authors:  Stefan Norin; Bo Björkstrand; Franz Rommel; Lars Timberg; Per-Ola Andersson; Johan Häggström; Anders Aldrin; Lotta Hansson
Journal:  Leuk Res       Date:  2014-11-13       Impact factor: 3.156

Review 7.  Health economic analysis of the burden of infusion reactions on patients, caregivers, and providers.

Authors:  Barry Fortner; Pamela Hallquist Viale
Journal:  Oncology (Williston Park)       Date:  2009-02       Impact factor: 2.990

8.  Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice: results of a multicenter study.

Authors:  Lee S Schwartzberg; Edward J Stepanski; Mark S Walker; Susan Mathias; Arthur C Houts; Barry V Fortner
Journal:  Support Care Cancer       Date:  2008-07-01       Impact factor: 3.603

Review 9.  A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.

Authors:  Kensei Tobinai; Christian Klein; Naoko Oya; Günter Fingerle-Rowson
Journal:  Adv Ther       Date:  2016-12-21       Impact factor: 3.845

10.  Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study.

Authors:  Véronique Leblond; Melih Aktan; Christelle M Ferra Coll; Caroline Dartigeas; Jens Kisro; Marco Montillo; João Raposo; Jean-Louis Merot; Susan Robson; Ekaterina Gresko; Francesc Bosch; Stephan Stilgenbauer; Robin Foà
Journal:  Haematologica       Date:  2018-07-05       Impact factor: 9.941
View more
  7 in total

Review 1.  COVID-19 in Patients with Hematologic Malignancies: Clinical Manifestations, Persistence, and Immune Response.

Authors:  Ivan Gur; Amir Giladi; Yonathan Nachum Isenberg; Ami Neuberger; Anat Stern
Journal:  Acta Haematol       Date:  2022-03-02       Impact factor: 3.068

Review 2.  Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors.

Authors:  Gabrielle Leclercq; Nathalie Steinhoff; Hélène Haegel; Donata De Marco; Marina Bacac; Christian Klein
Journal:  Oncoimmunology       Date:  2022-06-01       Impact factor: 7.723

3.  Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma.

Authors:  Constantine S Tam; Hang Quach; Andrew Nicol; Xavier Badoux; Hannah Rose; H Miles Prince; Michael F Leahy; Richard Eek; Nicholas Wickham; Sushrut S Patil; Jane Huang; Radha Prathikanti; Aileen Cohen; Rebecca Elstrom; William Reed; Jingjing Schneider; Ian W Flinn
Journal:  Blood Adv       Date:  2020-10-13

Review 4.  Clinical application of obinutuzumab for treating chronic lymphocytic leukemia.

Authors:  Chunyan Luan; Baoan Chen
Journal:  Drug Des Devel Ther       Date:  2019-08-19       Impact factor: 4.162

5.  Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.

Authors:  Richard Greil; Alessandra Tedeschi; Carol Moreno; Bertrand Anz; Loree Larratt; Martin Simkovic; Devinder Gill; John G Gribben; Ian W Flinn; Zhengyuan Wang; Leo W K Cheung; Aaron N Nguyen; Cathy Zhou; Lori Styles; Fatih Demirkan
Journal:  Ann Hematol       Date:  2021-05-20       Impact factor: 3.673

6.  Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia.

Authors:  Nicole Bourrier; Ivan Landego; Oliver Bucher; Mandy Squires; Erin Streu; Irena Hibbert; Theresa Whiteside; Spencer B Gibson; Marc Geirnaert; James B Johnston; David E Dawe; Versha Banerji
Journal:  BMC Cancer       Date:  2022-02-06       Impact factor: 4.430

7.  Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576.

Authors:  Januario E Castro; Paula A Lengerke-Diaz; Juliana Velez Lujan; Michael Y Choi; Eider F Moreno-Cortes; Jose V Forero; Juan Esteban Garcia-Robledo; Chaja Jacobs; Colin McCarthy; Alaina Heinen; Carlos I Amaya-Chanaga; Thomas J Kipps
Journal:  Adv Hematol       Date:  2022-01-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.